"Novartis announced today it will shortly submit a
revised filing package, including new data analyses, for
re-examination for conditional approval of RLX030, or serelaxin,"
the Basel-based drugmaker said in a statement.
Novartis, which had originally hoped to win approval for serelaxin
this year, said a revised opinion could be granted in the second
(Reporting by Katharina Bart)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.